In fiscal 2025, which ended Jan 3, 2026, Usana Health Sciences, Inc. generated $22.3 million of cash from operations. It spent $13.8 million on capital expenditures. That left free cash flow of $8.5 million. The company returned $27.5 million in share buybacks to shareholders.
USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the year before.
| Line |
FY 2026
Jul 4, 2026
|
FY 2025
Jan 3, 2026
|
FY 2023
Dec 28, 2024
|
FY 2023
Dec 30, 2023
|
FY 2022
Dec 31, 2022
|
FY 2022
Jan 1, 2022
|
FY 2020
Jan 2, 2021
|
FY 2019
Dec 28, 2019
|
FY 2018
Dec 29, 2018
|
FY 2017
Dec 30, 2017
|
FY 2014
Jan 3, 2015
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | |||||||||||
| Depreciation and amortization |
32
|
33
|
15
+11.5%
|
13
-2.6%
|
13
|
13
|
14
-6.8%
|
15
-12.5%
|
17
+4.5%
|
16
+19.5%
|
9
-2.6%
|
| Stock-based compensation |
14
|
14
|
15
+1.8%
|
15
+2.1%
|
13
|
14
|
14
-7.4%
|
16
+3.9%
|
15
-3.4%
|
15
-6.4%
|
10
+28.6%
|
| Operating cash flow |
28
|
22
|
61
-49.7%
|
71
-41.7%
|
104
|
121
|
160
+26.6%
|
127
-16.7%
|
152
+22.9%
|
124
|
105
+6.4%
|
| Investing | |||||||||||
| Capital expenditures |
12
|
14
|
10
-21.1%
|
14
+13.6%
|
10
|
13
|
15
-8.9%
|
17
+44.9%
|
11
-13.5%
|
13
-59.6%
|
20
+153.6%
|
| Investing cash flow |
-9
|
-10
|
-213
-1402.0%
|
-12
+15.6%
|
-12
|
-14
|
-34
-171.5%
|
47
+168.8%
|
-69
-434.8%
|
-13
|
-16
+24.7%
|
| Financing | |||||||||||
| Stock buybacks |
0
|
28
|
9
-94.7%
|
12
-93.5%
|
25
|
178
|
57
-62.0%
|
150
+42.3%
|
105
+110.8%
|
50
-22.6%
|
139
+667.6%
|
| Financing cash flow |
-5
|
-41
|
10
+105.3%
|
-14
+92.2%
|
-30
|
-181
|
-59
+60.9%
|
-152
-44.4%
|
-105
-109.2%
|
-50
|
-113
-1011.8%
|
| Change in cash | |||||||||||
| Effect of exchange rate |
—
|
—
|
—
|
—
|
—
|
—
|
—
|
-2
+84.6%
|
-11
|
—
|
—
|
| Net change in cash |
17
|
-23
|
-149
-105.8%
|
42
+158.0%
|
48
|
-72
|
78
+282.6%
|
20
+161.4%
|
-33
|
—
|
—
|
| Free cash flow |
16
|
9
|
51
-53.1%
|
56
-48.2%
|
94
|
108
|
145
+31.9%
|
110
-21.7%
|
141
+27.3%
|
111
|
85
-6.7%
|
| Per share | |||||||||||
| Free cash flow per share |
0.87
|
0.46
|
2.66
-50.2%
|
2.90
-45.6%
|
4.84
|
5.33
|
6.84
+41.6%
|
4.83
-15.4%
|
5.71
+27.6%
|
4.47
|
3.10
-51.6%
|
| Shareholder returns | |||||||||||
| Returned to shareholders |
0
|
28
|
9
|
12
|
25
|
178
|
57
|
150
|
105
|
50
|
139
|
| Share of free cash flow |
0.00%
|
322.62%
|
18.55%
|
20.66%
|
27.15%
|
163.96%
|
39.25%
|
136.16%
|
74.90%
|
45.23%
|
163.77%
|
| Ratios | |||||||||||
| Free cash flow margin |
1.74%
|
0.92%
|
5.96%
|
6.10%
|
9.36%
|
9.14%
|
12.81%
|
10.38%
|
11.83%
|
—
|
—
|
| Capital expenditures to revenue |
1.29%
|
1.49%
|
1.18%
|
1.57%
|
1.04%
|
1.08%
|
1.33%
|
1.56%
|
0.96%
|
—
|
—
|
| Stock-based compensation to revenue |
1.55%
|
1.49%
|
1.70%
|
1.58%
|
1.33%
|
1.21%
|
1.27%
|
1.46%
|
1.26%
|
—
|
—
|
| Cash conversion |
—
|
2.08x
|
1.45x
|
1.11x
|
1.50x
|
1.04x
|
1.29x
|
1.26x
|
1.21x
|
1.98x
|
1.37x
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. The first column is the trailing twelve months through the latest quarter. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.
Company profile
- Industry
- Medicinal Chemicals & Botanical Products (SIC 2833)
- Listed as
- USNA (NYSE)
- Fiscal year ends
- January 3
- Incorporated in
- UT
- Headquarters
- Salt Lake City, UT
- SEC filer status
- Accelerated filer
- SEC CIK
- 896264
- Former names
- USANA INC (until Apr 27, 2000)
Other Medicinal Chemicals & Botanical Products companies
- Definium Therapeutics, Inc. DFTX
- Regencell Bioscience Holdings Ltd RGC
- Curaleaf Holdings, Inc. CURLF
- Trulieve Cannabis Corp. TRLV
- Cronos Group Inc. CRON
- TFA Therapeutics, Inc. RAJAF
- Tilray Brands, Inc. TLRY
- SNDL Inc. SNDL
Source: SEC EDGAR filings. This is company-reported data, not investment advice.